Literature DB >> 29892472

Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure.

Cristiana Vitale1, Spoletini Ilaria1, Giuseppe Mc Rosano1.   

Abstract

Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described.

Entities:  

Keywords:  Exercise tolerance; heart failure; intravenous iron; ivabradine; trimetazidine

Year:  2018        PMID: 29892472      PMCID: PMC5971671          DOI: 10.15420/cfr.2018:8:2

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN: 2057-7540


  43 in total

1.  Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.

Authors:  Aidan P Bolger; Frederick R Bartlett; Helen S Penston; Justin O'Leary; Noel Pollock; Raffi Kaprielian; Callum M Chapman
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

2.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.

Authors:  J R Hampton; D J van Veldhuisen; F X Kleber; A J Cowley; A Ardia; P Block; A Cortina; L Cserhalmi; F Follath; G Jensen; J Kayanakis; K I Lie; G Mancia; A M Skene
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

3.  The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines.

Authors:  Ivan Milinković; Giuseppe Rosano; Yuri Lopatin; Petar M Seferović
Journal:  Card Fail Rev       Date:  2016-11

4.  Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.

Authors:  A E Bagriy; E V Schukina; O V Samoilova; O A Pricolota; S I Malovichko; A V Pricolota; E A Bagriy
Journal:  Adv Ther       Date:  2015-02-21       Impact factor: 3.845

5.  Trimetazidine shortens QTc interval in patients with ischemic heart failure.

Authors:  Gregor Zemljic; Matjaz Bunc; Bojan Vrtovec
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-12-04       Impact factor: 2.457

6.  Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.

Authors:  Jorge Eduardo Toblli; Alejandra Lombraña; Patricio Duarte; Federico Di Gennaro
Journal:  J Am Coll Cardiol       Date:  2007-10-23       Impact factor: 24.094

7.  Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.

Authors:  Darlington O Okonko; Agnieszka Grzeslo; Tomasz Witkowski; Amit K J Mandal; Robert M Slater; Michael Roughton; Gabor Foldes; Thomas Thum; Jacek Majda; Waldemar Banasiak; Constantinos G Missouris; Philip A Poole-Wilson; Stefan D Anker; Piotr Ponikowski
Journal:  J Am Coll Cardiol       Date:  2008-01-15       Impact factor: 24.094

Review 8.  Trimetazidine improves exercise tolerance in patients with ischemic heart disease : A meta-analysis.

Authors:  Y Zhao; L Peng; Y Luo; S Li; Z Zheng; R Dong; J Zhu; J Liu
Journal:  Herz       Date:  2015-12-14       Impact factor: 1.443

9.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur Heart J       Date:  2016-05-20       Impact factor: 29.983

10.  Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Barbara Sposato; Giuseppe Mercuro; Massimo Fini
Journal:  Cardiovasc Diabetol       Date:  2003-11-28       Impact factor: 9.951

View more
  7 in total

Review 1.  Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?

Authors:  Andrew Sindone; Wolfram Doehner; Nicolas Manito; Theresa McDonagh; Alain Cohen-Solal; Thibaud Damy; Julio Núñez; Otmar Pfister; Peter van der Meer; Josep Comin-Colet
Journal:  J Clin Med       Date:  2022-05-25       Impact factor: 4.964

2.  Clinical case: heart failure and ischaemic heart disease.

Authors:  Giuseppe M C Rosano
Journal:  Eur Heart J Suppl       Date:  2019-04-10       Impact factor: 1.803

3.  Monitoring of iron status in patients with heart failure.

Authors:  Ewa A Jankowska; Michał Tkaczyszyn; Marcin Drozd; Piotr Ponikowski
Journal:  Eur Heart J Suppl       Date:  2019-12-31       Impact factor: 1.803

4.  Care plans for the older heart failure patient.

Authors:  Loreena Hill; Matthew A Carson; Cristiana Vitale
Journal:  Eur Heart J Suppl       Date:  2019-12-23       Impact factor: 1.803

5.  Frailty in patients with heart failure.

Authors:  Cristiana Vitale; Izabella Uchmanowicz
Journal:  Eur Heart J Suppl       Date:  2019-12-23       Impact factor: 1.803

Review 6.  Prioritizing symptom management in the treatment of chronic heart failure.

Authors:  Aaron O Koshy; Elisha R Gallivan; Melanie McGinlay; Sam Straw; Michael Drozd; Anet G Toms; John Gierula; Richard M Cubbon; Mark T Kearney; Klaus K Witte
Journal:  ESC Heart Fail       Date:  2020-08-05

Review 7.  Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?

Authors:  Kirsten T Nijholt; Pablo I Sánchez-Aguilera; Suzanne N Voorrips; Rudolf A de Boer; B Daan Westenbrink
Journal:  Eur J Heart Fail       Date:  2022-01-09       Impact factor: 17.349

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.